These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2502841)

  • 1. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: current view.
    Langston JW
    Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial for Parkinson's disease?
    Lewin R
    Science; 1985 Nov; 230(4725):527-8. PubMed ID: 3931220
    [No Abstract]   [Full Text] [Related]  

  • 6. MAO type B inhibitors as adjunct to L-dopa therapy.
    Youdim MB; Finberg JP
    Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
    [No Abstract]   [Full Text] [Related]  

  • 7. (-)Deprenyl in perspective: prophylaxis for Parkinson's disease?
    Sandler M
    J Neural Transm Suppl; 1986; 22():107-15. PubMed ID: 3097254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPTP, selegiline, and parkinsonism.
    Akos K
    Lancet; 1987 Jan; 1(8523):38-9. PubMed ID: 2879111
    [No Abstract]   [Full Text] [Related]  

  • 10. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
    Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
    [No Abstract]   [Full Text] [Related]  

  • 11. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigral degeneration in Parkinson's disease.
    Rinne JO
    Mov Disord; 1993; 8 Suppl 1():S31-5. PubMed ID: 8302305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease.
    Lieberman AN
    Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
    [No Abstract]   [Full Text] [Related]  

  • 15. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.
    Cohen G; Pasik P; Cohen B; Leist A; Mytilineou C; Yahr MD
    Eur J Pharmacol; 1984 Oct; 106(1):209-10. PubMed ID: 6442232
    [No Abstract]   [Full Text] [Related]  

  • 16. Monoamine oxidase inhibitors and their pharmacological significance.
    Sandler M
    Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selegiline in Parkinson's disease.
    Calne DB
    BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings].
    Ambrozi L; Birkmayer W; Riederer P; Youdim MB
    Br J Pharmacol; 1976 Nov; 58(3):423P-424P. PubMed ID: 791430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.